מדינה: קנדה
שפה: אנגלית
מקור: Health Canada
BACLOFEN
STERIMAX INC
M03BX01
BACLOFEN
10MG
SOLUTION
BACLOFEN 10MG
INTRATHECAL
20ML
Prescription
GABA-DERIVATIVE SKELETAL MUSCLE RELAXANTS
Active ingredient group (AIG) number: 0113246005; AHFS:
APPROVED
2014-05-02
PRODUCT MONOGRAPH PR BACLOFEN INJECTION 0.05 mg/mL, 0.5 mg/mL, and 2 mg/mL For intrathecal injection and intrathecal infusion only ANTISPASTIC AGENT SteriMax Inc. 2770 Portland Drive Oakville, Ontario L6H 6R4 DATE OF REVISION: May 5, 2021 CONTROL NO.: 246780 Page 2 of 29 PRODUCT MONOGRAPH PR BACLOFEN INJECTION 0.05 mg/mL, 0.5 mg/mL, and 2 mg/mL For intrathecal injection and intrathecal infusion only THERAPEUTIC CLASSIFICATION Antispastic Agent CLINICAL PHARMACOLOGY The precise mechanisms of action of baclofen as an antispastic agent are not fully understood. Baclofen inhibits both monosynaptic and polysynaptic reflex transmission at the spinal level, possibly by decreasing excitatory neurotransmitter release from primary afferent terminals. Actions at supraspinal sites may also contribute to its clinical effect. Baclofen is an analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), and may exert its effects by stimulation of the GABA B receptor subtype. Baclofen has been shown to have general Central Nervous System (CNS) depressant properties as indicated by the production of sedation with tolerance, somnolence, ataxia, and respiratory and cardiovascular depression. A dose-dependent inhibitory effect on erectile function has been shown in men through GABA B receptor stimulation. In neurological diseases associated with spasm of the skeletal muscles, baclofen injection may have beneficial action on reflex muscle contractions, painful spasm, automatism, hyperreflexia, trismus, and clonus. Neuromuscular transmission is not affected by baclofen. Baclofen may also reduce pain associated with spasticity. PHARMACODYNAMICS OF BACLOFEN INJECTION: INTRATHECAL BOLUS: The onset of action is generally half an hour to one hour after administration of an intrathecal bolus dose. Peak antispastic effect is seen at approximately 4 hours after dosing and effects may last 4 to 8 hours. Onset, peak response, and duration of action vary with individual patients depending on the dose and severity of symptoms. CONTIN קרא את המסמך השלם